Beta3 adrenergic receptor agonist crystal forms, processes for the production thereof, and uses thereof
AssigneePfizer Inc.
InventorsJoseph F. Krzyaniak, Jennifer A. Lafontaine
Life of this patent
Estimating the term…
Abstract
The present invention provides the tosylate salt of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol, the monohydrate of such salt, processes useful in the preparation of such salt and such monohydrate, pharmaceutical compositions comprising such salt, or such monohydrate, methods of treating β3-adrenergic receptor-mediated diseases, conditions, and disorders in a mammal using such salt, such monohydrate, or such pharmaceutical compositions; and methods of increasing the content of lean meat in edible animals using such salt, such monohydrate, or such pharmaceutical compositions.
Claims12
(R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), ρ-toluenesulfonate salt.
(R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), ρ-toluenesulfonate salt, monohydrate.
A pharmaceutical composition comprising
- (i) a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), ρ-toluenesulfonate salt;
- and.
- (ii) a pharmaceutically acceptable carrier, vehicle, or diluent.
A pharmaceutical composition comprising
- (i) a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), ρ-toluenesulfonate salt, monohydrate;
- and
- (ii) a pharmaceutically acceptable carrier, vehicle, or diluent.
A method of treating a β3-adrenergic receptor-mediated disease, condition, or disorder comprising the step of administering to a mammal in need of such treatment a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), ρ-toluenesulfonate salt;
- or (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), p-toluenesulfonate salt, monohydrate.
A method of treating a β3-adrenergic receptor-mediated disease, condition, or disorder comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition comprising
- (i) a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), ρ-toluenesulfonate salt;
- and
- (ii) a pharmaceutically acceptable carrier, vehicle, or diluent.
A method of treating a β3-adrenergic receptor-mediated disease, condition, or disorder comprising the step of administering to a mammal in need of such treatment a pharmaceutical composition comprising
- (i) a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), p-toluenesulfonate salt, monohydrate;
- and
- (ii) a pharmaceutically acceptable carrier, vehicle, or diluent.
A method of increasing lean meat content of an edible animal which method comprises administering to said edible animal a lean meat increasing amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), ρ-toluenesulfonate salt;
- or (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), ρ-toluenesulfonate salt, monohydrate.
A method of increasing lean meat content of an edible animal which method comprises administering to said edible animal a lean meat increasing amount of a pharmaceutical composition comprising
- (i) a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), ρ-toluenesulfonate salt;
- and
- (ii) a pharmaceutically acceptable carrier, vehicle, or diluent.
A method of increasing lean meat content of an edible animal which method comprises administering to said edible animal a lean meat increasing amount of a pharmaceutical composition comprising
- (i) a therapeutically effective amount of (R)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol), p-toluenesulfonate salt, monohydrate;
- and
- (ii) a pharmaceutically acceptable carrier, vehicle, or diluent.
Dependencies are inferred from the claim text.